Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/BOR.0000000000000111 http://scihub22266oqcxt.onion/10.1097/BOR.0000000000000111 C4591932!4591932!25191993     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Rheumatol 2014 ; 26 (6): 630-6 Nephropedia Template TP {{tp|p=25191993|t=2014. Update on scleroderma-associated interstitial lung disease |pdf=|usr=}}{{25191993}} gab.com Text Update on scleroderma-associated interstitial lung disease JO: Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=25191993 #FOAvip Systemic sclerosis (SSc), or scleroderma, is a heterogeneous and complex autoimmune disease characterized by varying degrees of skin and organ fibrosis and obliterative vasculopathy. The disease results in significant morbidity and mortality and to date available treatments are limited. Lung involvement is currently the leading cause of death of patients with SSc. Over the past year, significant advances have been made in our understanding of SSc-associated lung disease and this review attempts to encapsulate these most recent findings and place them in context. We divide our discussion of the most recent literature into 1) clinical aspects of SSc lung management, including classification, imaging, biomarkers, and treatment; 2) promising new animal models that may improve our ability to accurately study this disease; and 3) studies that advance or change our understanding of lung disease pathogenesis, thereby raising the potential for new targets for therapeutic intervention. The goal of this review is to highlight and summarize the most significant studies of the past year and to bring clinicians and researchers alike in the field up to date. Twit Text FOAVip Update on scleroderma-associated interstitial lung disease ????Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=25191993 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25191993 #FOAvip English Wikipedia <ref>{{Cite pmid|25191993}}</ref> Update on scleroderma-associated interstitial lung disease #MMPMID25191993 Fan MH; Feghali-Bostwick CA; Silver RM Curr Opin Rheumatol 2014[Nov]; 26 (6): 630-6 PMID25191993show ga Systemic sclerosis (SSc), or scleroderma, is a heterogeneous and complex autoimmune disease characterized by varying degrees of skin and organ fibrosis and obliterative vasculopathy. The disease results in significant morbidity and mortality and to date available treatments are limited. Lung involvement is currently the leading cause of death of patients with SSc. Over the past year, significant advances have been made in our understanding of SSc-associated lung disease and this review attempts to encapsulate these most recent findings and place them in context. We divide our discussion of the most recent literature into 1) clinical aspects of SSc lung management, including classification, imaging, biomarkers, and treatment; 2) promising new animal models that may improve our ability to accurately study this disease; and 3) studies that advance or change our understanding of lung disease pathogenesis, thereby raising the potential for new targets for therapeutic intervention. The goal of this review is to highlight and summarize the most significant studies of the past year and to bring clinicians and researchers alike in the field up to date. äUpdate on scleroderma-associated interstitial lung disease (epmc).pdf DeepDyve Pubget Overpricing